Cargando…

Procarbazine and CCNU Chemotherapy for Recurrent Glioblastoma with MGMT Promoter Methylation

BACKGROUND: While procarbazine, CCNU (lomustine), and vincristine (PCV) has been an alternative chemotherapy option for malignant gliomas, it is worth investigating whether the combination of only procarbazine and CCNU is comparable because vincristine adds toxicity with uncertain benefit. The purpo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Se-Hyuk, Yoo, Heon, Chang, Jong Hee, Kim, Chae-Yong, Chung, Dong Sup, Kim, Se Hoon, Park, Sung-Hae, Lee, Youn Soo, Yang, Seung Ho
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990446/ https://www.ncbi.nlm.nih.gov/pubmed/29892208 http://dx.doi.org/10.3346/jkms.2018.33.e167

Ejemplares similares

Procarbazine, CCNU, and Vincristine Chemotherapy in Gliomatosis Cerebri
por: Lee, Hyun Gon, et al.
Publicado: (2014)

Procarbazine, CCNU and vincristine (PCV) versus temozolomide chemotherapy for patients with low-grade glioma: a systematic review
por: Hafazalla, Karim, et al.
Publicado: (2018)

First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
por: Lazaridis, Lazaros, et al.
Publicado: (2022)

Clinical feasibility of modified procarbazine and lomustine chemotherapy without vincristine as a salvage treatment for recurrent adult glioma
por: Ahn, Stephen, et al.
Publicado: (2022)

Appraisal of re-irradiation for the recurrent glioblastoma in the era of MGMT promotor methylation
por: Kim, Il Han
Publicado: (2019)

Prognosis of Glioblastoma With Oligodendroglioma Component is Associated With the IDH1 Mutation and MGMT Methylation Status()
por: Myung, Jae Kyung, et al.
Publicado: (2014)

Efficacy of Procarbazine, Lomustine, and Vincristine Chemotherapy for Recurrent Primary Central Nervous System Lymphomas
por: Kim, Young-Joo, et al.
Publicado: (2015)

Association between MGMT Enhancer Methylation and MGMT Promoter Methylation, MGMT Protein Expression, and Overall Survival in Glioblastoma
por: Zappe, Katja, et al.
Publicado: (2023)

Priming with low doses of methyl-CCNU reduce the toxicity of high doses of methyl-CCNU and melphalan, and increase the lifespan of mice implanted with Lewis lung carcinoma.
por: Zimber, A., et al.
Publicado: (1988)

MGMT promoter methylation in Peruvian patients with glioblastoma
por: Belmar-Lopez, Carolina, et al.
Publicado: (2018)

Chemopotentiation of CCNU metabolites by misonidazole.
por: Mulcahy, R. T.
Publicado: (1985)

An evaluation of MGMT promoter methylation within the methylation subclasses of glioblastoma
por: Alnahhas, Iyad, et al.
Publicado: (2020)

Prognostic Role of Methylation Status of the MGMT Promoter Determined Quantitatively by Pyrosequencing in Glioblastoma Patients
por: Kim, Dae Cheol, et al.
Publicado: (2016)

MGMT Methylation Status: The Advent of Stratified Therapy in Glioblastoma?
por: Hau, Peter, et al.
Publicado: (2007)

Combination chemotherapy versus temozolomide for patients with methylated MGMT (m-MGMT) glioblastoma: results of computational biological modeling to predict the magnitude of treatment benefit
por: Castro, Michael, et al.
Publicado: (2021)

Efficacy and safety of metformin plus low-dose temozolomide in patients with recurrent or refractory glioblastoma: a randomized, prospective, multicenter, double-blind, controlled, phase 2 trial (KNOG-1501 study)
por: Yoon, Wan-Soo, et al.
Publicado: (2023)

Protection of rat spermatogenic epithelium from damage induced by procarbazine chemotherapy.
por: Glode, L. M., et al.
Publicado: (1990)

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status
por: Thon, Niklas, et al.
Publicado: (2013)

Radiomics and MGMT promoter methylation for prognostication of newly diagnosed glioblastoma
por: Sasaki, Takahiro, et al.
Publicado: (2019)

The MGMT promoter single-nucleotide polymorphism rs1625649 had prognostic impact on patients with MGMT methylated glioblastoma
por: Hsu, Chih-Yi, et al.
Publicado: (2017)

Chemosensitization by misonidazole in CCNU-treated spheroids and tumours.
por: Durand, R. E., et al.
Publicado: (1987)

In vivo combination of misonidazole and the chemotherapeutic agent CCNU.
por: Siemann, D. W.
Publicado: (1981)

Cisplatin and CCNU synergism in spheroid cell subpopulations.
por: Durand, R. E.
Publicado: (1990)

DGKI Methylation Status Modulates the Prognostic Value of MGMT in Glioblastoma Patients Treated with Combined Radio-Chemotherapy with Temozolomide
por: Etcheverry, Amandine, et al.
Publicado: (2014)

Prognostic value of TP53 expression and MGMT methylation in glioblastoma patients treated with temozolomide combined with other chemotherapies
por: Kurdi, Maher, et al.
Publicado: (2021)

Extraneural Metastases of Glioblastoma without Simultaneous Central Nervous System Recurrence
por: Kim, Wonki, et al.
Publicado: (2014)

MRI texture features as biomarkers to predict MGMT methylation status in glioblastomas
por: Korfiatis, Panagiotis, et al.
Publicado: (2016)

Tim-3 Expression and MGMT Methylation Status Association With Survival in Glioblastoma
por: Zhang, Ji, et al.
Publicado: (2020)

Identifying the optimal cutoff point for MGMT promoter methylation status in glioblastoma
por: Nguyen, Ngan, et al.
Publicado: (2021)

Prognostic Impact of the Combination of MGMT Methylation and TERT Promoter Mutation in Glioblastoma
por: Tunthanathip, Thara, et al.
Publicado: (2021)

Peritumoral ADC Values Correlate with the MGMT Methylation Status in Patients with Glioblastoma
por: Ladenhauf, Valentin Karl, et al.
Publicado: (2023)

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
por: Yung, W K A, et al.
Publicado: (2000)

Real-time methylation-specific PCR for the evaluation of methylation status of MGMT gene in glioblastoma
por: Yoshioka, Masaki, et al.
Publicado: (2018)

Toxicity Profile of Procarbazine Lomustine and Vincristine Chemotherapy in Low-Grade Glioma - Retrospective Review
por: Irfan, Nabia, et al.
Publicado: (2020)

Temozolomide Salvage Chemotherapy for Recurrent Anaplastic Oligodendroglioma and Oligo-Astrocytoma
por: Gwak, Ho-Shin, et al.
Publicado: (2013)

Enhancement of CCNU cytotoxicity by misonidazole: possible therapeutic gain.
por: Hirst, D. G., et al.
Publicado: (1982)

Response of two mouse tumours to hyperthermia with CCNU or melphalan.
por: Joiner, M. C., et al.
Publicado: (1982)

Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma
por: Woo, Jong-Yun, et al.
Publicado: (2015)

GEN-06 CLINICAL COURSE AFTER TUMOR RECURRENCE OF MGMT HYPERMETHYLATED GLIOBLASTOMA
por: Adachi, Junichi, et al.
Publicado: (2019)

Correlation of MGMT promoter methylation status with gene and protein expression levels in glioblastoma
por: Uno, Miyuki, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_cv0r85nlsiod8uq6v5tj56dln6